[go: up one dir, main page]

PE20211392A1 - Separacion enantiomerica de nicotina racemica mediante adicion de un enantiomero de acido tartarico o,o'-disustituido - Google Patents

Separacion enantiomerica de nicotina racemica mediante adicion de un enantiomero de acido tartarico o,o'-disustituido

Info

Publication number
PE20211392A1
PE20211392A1 PE2020000799A PE2020000799A PE20211392A1 PE 20211392 A1 PE20211392 A1 PE 20211392A1 PE 2020000799 A PE2020000799 A PE 2020000799A PE 2020000799 A PE2020000799 A PE 2020000799A PE 20211392 A1 PE20211392 A1 PE 20211392A1
Authority
PE
Peru
Prior art keywords
enantiomer
tartaric acid
nicotine
disustituted
addition
Prior art date
Application number
PE2020000799A
Other languages
English (en)
Inventor
Beat Weber
Ben Pan
Original Assignee
Siegfried Ag
Contraf Nicotex Tobacco Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siegfried Ag, Contraf Nicotex Tobacco Gmbh filed Critical Siegfried Ag
Publication of PE20211392A1 publication Critical patent/PE20211392A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un metodo de separacion de la nicotina racemica de formula (I-a), en forma de una mezcla de los enantiomeros R y S, en la (R)- y la (S)-nicotina enantiomericamente puras representadas por la formula (I-b) y la formula (I-c), mediante la adicion de una mezcla del enantiomero L y el enantiomero D de un acido tartarico O,O'-disustituido, en el que la relacion molar del enantiomero L con respecto al enantiomero D es de 80:20 a 95:5 y la obtencion de la (S)-nicotina de formula (I-b), o mediante la adicion de acido O,O'-dibenzoil-D-tartarico y la obtencion de la (R)-nicotina de formula (I-c).
PE2020000799A 2017-12-22 2018-12-18 Separacion enantiomerica de nicotina racemica mediante adicion de un enantiomero de acido tartarico o,o'-disustituido PE20211392A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17210181 2017-12-22
PCT/EP2018/085444 WO2019121649A1 (en) 2017-12-22 2018-12-18 Enantiomeric separation of racemic nicotine by addition of an o,o'-disubstituted tartaric acid enantiomer

Publications (1)

Publication Number Publication Date
PE20211392A1 true PE20211392A1 (es) 2021-07-27

Family

ID=60782088

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000799A PE20211392A1 (es) 2017-12-22 2018-12-18 Separacion enantiomerica de nicotina racemica mediante adicion de un enantiomero de acido tartarico o,o'-disustituido

Country Status (28)

Country Link
US (1) US11279685B2 (es)
EP (1) EP3710437B1 (es)
JP (1) JP7030208B2 (es)
KR (1) KR20200103730A (es)
CN (1) CN111527077B (es)
AU (1) AU2018391657B2 (es)
BR (1) BR112020012458A2 (es)
CA (1) CA3085208C (es)
CL (1) CL2020001656A1 (es)
CY (1) CY1125900T1 (es)
DK (1) DK3710437T3 (es)
ES (1) ES2940319T3 (es)
FI (1) FI3710437T3 (es)
HR (1) HRP20230119T1 (es)
HU (1) HUE061702T2 (es)
IL (1) IL275585B2 (es)
LT (1) LT3710437T (es)
MY (1) MY193072A (es)
NZ (1) NZ765535A (es)
PE (1) PE20211392A1 (es)
PL (1) PL3710437T3 (es)
PT (1) PT3710437T (es)
RS (1) RS64017B1 (es)
RU (1) RU2753492C1 (es)
SG (1) SG11202005641XA (es)
SI (1) SI3710437T1 (es)
WO (1) WO2019121649A1 (es)
ZA (1) ZA202003683B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121644A1 (en) 2017-12-22 2019-06-27 Siegfried Ag Preparation of racemic nicotine by reaction of ethyl nicotinate with n-vinylpyrrolidone in the presence of an alcoholate base and subsequent process steps
LU101511B1 (en) * 2019-12-02 2021-06-04 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a parenteral administration and a process for the preparation of an injectable substance
CN111187250B (zh) * 2020-01-08 2023-04-07 深圳黑尔格科技有限公司 一种拆分式制备光学活性尼古丁的方法
CN114644614B (zh) * 2021-04-21 2023-03-28 黄冈中有生物科技有限公司 一种左旋烟碱的制备方法
CN115260088A (zh) * 2021-04-30 2022-11-01 武汉中有药业有限公司 烟碱及其中间体的制备方法
CN113416180A (zh) * 2021-08-09 2021-09-21 东莞市鸿馥生物科技有限公司 一种(s)-1-甲基-2-(3-吡啶基)吡咯烷的拆分方法
CN114249711A (zh) * 2022-03-02 2022-03-29 北京邦克凯姆医药科技有限公司 一种拆分制备尼古丁的方法
CN114671852A (zh) * 2022-04-24 2022-06-28 仙居两山生物科技有限公司 一种高纯度左旋烟碱医药中间体的制备方法
CN115093394B (zh) * 2022-07-20 2024-10-18 北京世桥生物制药有限公司 S-(-)-尼古丁(-)-二苯甲酰-l-酒石酸盐晶型、制备方法及应用
CN115286615A (zh) * 2022-09-01 2022-11-04 深圳市真味生物科技有限公司 一种消旋尼古丁的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003342259A (ja) 2001-12-21 2003-12-03 Toray Ind Inc 光学活性シスピペリジン誘導体の製造法
JP2006335639A (ja) 2003-01-23 2006-12-14 Nagase & Co Ltd 光学活性なフルルビプロフェンの製造方法
CN102617547B (zh) 2011-01-27 2016-02-10 上海特化医药科技有限公司 一种制备消旋尼古丁的方法
US8378111B2 (en) 2011-02-02 2013-02-19 Divi's Laboratories, Ltd. Process for the resolution of (R,S)-nicotine
US8367837B2 (en) 2011-02-14 2013-02-05 Divi's Laboratories, Ltd. Process for the preparation of (R,S)-nicotine
US9556142B2 (en) 2014-10-22 2017-01-31 Next Generation Labs, LLC Process for the preparation of (R,S)-nicotine
US9809567B2 (en) * 2014-12-09 2017-11-07 Njoy, Llc Synthesis and resolution of nicotine
US10610526B2 (en) 2015-12-30 2020-04-07 Next Generation Labs, LLC Nicotine replacement therapy products comprising synthetic nicotine
US10421739B2 (en) 2016-01-08 2019-09-24 Council Of Scientific & Industrial Research Process for the preparation of nicotine
WO2019121644A1 (en) 2017-12-22 2019-06-27 Siegfried Ag Preparation of racemic nicotine by reaction of ethyl nicotinate with n-vinylpyrrolidone in the presence of an alcoholate base and subsequent process steps

Also Published As

Publication number Publication date
IL275585B1 (en) 2023-05-01
US11279685B2 (en) 2022-03-22
PL3710437T3 (pl) 2023-04-11
RU2753492C1 (ru) 2021-08-17
IL275585B2 (en) 2023-09-01
CY1125900T1 (el) 2024-09-20
JP7030208B2 (ja) 2022-03-04
MY193072A (en) 2022-09-26
NZ765535A (en) 2024-03-22
CA3085208C (en) 2023-05-23
FI3710437T3 (fi) 2023-03-23
EP3710437A1 (en) 2020-09-23
RS64017B1 (sr) 2023-03-31
PT3710437T (pt) 2023-03-17
SG11202005641XA (en) 2020-07-29
BR112020012458A2 (pt) 2020-11-24
ZA202003683B (en) 2023-01-25
KR20200103730A (ko) 2020-09-02
LT3710437T (lt) 2023-04-25
CL2020001656A1 (es) 2020-11-13
WO2019121649A1 (en) 2019-06-27
AU2018391657A1 (en) 2020-07-09
HRP20230119T1 (hr) 2023-03-31
AU2018391657B2 (en) 2022-03-10
JP2021515029A (ja) 2021-06-17
ES2940319T3 (es) 2023-05-05
HUE061702T2 (hu) 2023-08-28
CA3085208A1 (en) 2019-06-27
IL275585A (en) 2020-08-31
EP3710437B1 (en) 2022-12-14
US20200331883A1 (en) 2020-10-22
CN111527077B (zh) 2023-03-10
CN111527077A (zh) 2020-08-11
SI3710437T1 (sl) 2023-04-28
DK3710437T3 (da) 2023-02-20

Similar Documents

Publication Publication Date Title
PE20211392A1 (es) Separacion enantiomerica de nicotina racemica mediante adicion de un enantiomero de acido tartarico o,o'-disustituido
JOP20200225A1 (ar) مشتق كوينولين عالي النقاء وطريقة لإنتاجه
MD20220052A2 (ro) Procedeu de preparare a compuşilor izoxazolinici enantiomeric îmbogăţiţi şi a solvatului de toluen cristalin al (S)-afoxolanerului
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
CL2018000036A1 (es) Derivados etinilo
EA201891437A1 (ru) Способ разделения энантиомеров пиперазиновых производных
JOP20200267A1 (ar) طريقة لتحضير (4s)-4-(4-سيانو-2-ميثوكسي فنيل)-5- إيثوكسي-8،2- ثنائي ميثيل-4،1- ثنائي هيدرو-1-6-نفثيريدين-3-كربوكس-اميد عن طريق فصل راسيمات بواسطة استرات حمض طرطريك دياستريومرية
AR071694A1 (es) Procedimiento para la obtencion de arilcarboxamidas
MY191236A (en) Diorganylphosphinic acid salts, method for the production thereof and the use thereof
EA201692488A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
MX2019001465A (es) Metodo de produccion de cetoenoles ciclicos sustituidos con espirocetales.
WO2018125983A8 (en) Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
EA201391721A1 (ru) Способ получения полиморфной формы i эторикоксиба
MX2021005343A (es) Proceso para la preparacion de isoxazolinas opticamente enriquecidas.
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
EA202091442A3 (ru) Способ превращения s-энантиомера в его рацемическую форму
MX2022002568A (es) Proceso para preparar (r)-4-aminoindano y amidas correspondientes.
PE20170706A1 (es) Derivados del acido abscisico sustituido en 3'
PH12015501840A1 (en) Production method of pyridazinone compounds
EA201992380A1 (ru) Способ получения энантиомеров пирлиндола и их солей
EA201791098A1 (ru) Способ синтеза производных бензазепина
IN2014DN06213A (es)
CL2020001285A1 (es) Método de producción de un compuesto intermedio para sintetizar un medicamento.
PL408997A1 (pl) Sposób otrzymywania (-)-enancjomeru (-)-(1R,4S)-2-azabicyklo[2.2.1]hept-5-en-3-onu
UA114555C2 (uk) Спосіб одержання гідрохлориду 1-(трифлуорометил)циклопропанаміну